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PORRECTION
iviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E, for the PROVE IT-TIMI 22 Investigators. Can
ow-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive
tatin Therapy: A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol 2005;46:1411–6.
n this paper, an analytical inconsistency and typographical errors were noted by the authors. Throughout the paper, the total number of
ubjects should be 1,837. The distribution by achieved four-month low-density lipoprotein (LDL) should be 181 (10%) 100 mg/dl, 256
14%) 80 to 100 mg/dl, 576 (31%) 60 to 80 mg/dl, 631 (34%) 40 to 60 mg/dl, and 193 (11%) subjects 40 mg/dl. The baseline
DL values listed in Table 1 are correct, but they are incorrect in the second paragraph of the Results section. A corrected Table 2 is
rinted below.
hese changes do not affect the Discussion or Conclusions of this paper. The authors regret these errors.
doi:10.1016/j.jacc.2005.12.002
able 2. Major Safety and Efficacy Outcomes
Achieved LDL Cholesterol (mg/dl)
p Value*
>80–100
n  256
>60–80
n  576
>40–60
n  631
<40
n  193
uscle side effects (%)
Myalgia 5.1 5.4 6.0 5.7 0.61
Myositis 0.4 0.9 0.8 0 0.72
CK 3  ULN 2.3 0.7 1.9 1.0 0.81
CK 10  ULN 0.4 0 0.3 0 0.81
Rhabdomyolysis 0 0 0 0 —
iver side effects (%)
ALT 3  ULN 3.1 3.0 3.2 2.6 0.87
Study drug discontinued due to LFT 2.0 2.6 2.4 1.6 0.79
ther (%)
Hemorrhagic stroke 0.4 0.2 0 0 0.13
Retinal AE 0.4 0.9 1.0 0 0.87
Suicide/trauma death 0 0 0 0 —
Study drug discontinued due to any AE 10.2 9.4 9.7 9.8 0.96
ajor efficacy measures (KM estimates)
Death 1.1 1.4 1.3 0.5 0.59
CHD death 0.5 0.5 0.6 0.0 0.80
Myocardial infarction 10.3 6.8 4.5 6.3 0.009
Any stroke 0.8 0.9 0.6 1.6 0.57
Primary composite 26.1 22.2 20.4 20.4 0.10
Chi-square test for trend of safety end points, test for trend of the survivor function for KM estimates (efficacy).
AE  adverse event; ALT  alanine aminotransferase; CHD  coronary heart disease; CK  creatine kinase; LDL  low-density lipoprotein; LFT  liver function test;
M  Kaplan-Meier; ULN  upper limit of normal.
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